Added by | amaraver |
---|---|
Group name | EquipeAM |
Item Type | Attachment |
Title | PubMed entry |
URL | http://www.ncbi.nlm.nih.gov/pubmed/35278766 |
Accessed | 2022/08/31 - 16:13:39 |
Date Added | 2022/08/31 - 14:13:39 |
Date Modified | 2022/08/31 - 14:13:39 |
Parent item | Randomized phase 3 study of the anti-disialoganglioside antibody dinutuximab and irinotecan vs irinotecan or topotecan for second-line treatment of small cell lung cancer |